Extensive diagnostic work-up for patients with carcinoma of unknown primary

被引:0
作者
L. Meijer
R. H. A. Verhoeven
I. H. J. T. de Hingh
A. J. van de Wouw
H. W. M. van Laarhoven
V. E. P. P. Lemmens
C. Loef
机构
[1] Comprehensive Cancer Organisation Netherlands,Department of Research & Development
[2] Radboud University Medical Center,Department of Surgery
[3] Catharina Hospital Eindhoven,Department of Surgical Oncology
[4] VieCuri Hospital Venlo/Venray,Department of Medical Oncology
[5] University of Amsterdam,Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers
[6] Erasmus MC University Medical Center,Department of Public Health
来源
Clinical & Experimental Metastasis | 2021年 / 38卷
关键词
Unknown primary carcinoma; Diagnostics; Population-based; Guideline; Oncology;
D O I
暂无
中图分类号
学科分类号
摘要
Patients with carcinoma of unknown primary (CUP) present with metastatic disease without an identified primary tumour. The unknown site of origin makes the diagnostic work-up and treatment challenging. Since little information is available regarding diagnostic work-up and treatment in daily practice, we collected and analysed these in a patient cohort with regard to the recommendations of the national CUP guideline. Data of 161 patients diagnosed with CUP in 2014 or 2015 were extracted from the Netherlands Cancer Registry (NCR) and supplemented with diagnostic work-up information from patient files and analysed. Patients underwent an average of five imaging studies during the diagnostic phase (range 1–17). From the tests as recommended in the national guideline on CUP, a chest X-ray was most commonly performed (73%), whereas a PET-CT was done in one out of four patients (24%). Biopsies were taken in 86% of the study population, with Cytokeratin 7 being the most frequently tested histopathological marker (73%). Less than half of patients received therapy (42%). CUP patients undergo extensive diagnostic work-up. The performance status did not influence the extent of the diagnostic work-up in CUP patients, but it was an important factor for receiving treatment.
引用
收藏
页码:231 / 238
页数:7
相关论文
共 39 条
[1]  
Varadhachary GR(2007)Carcinoma of unknown primary origin Gastrointest Cancer Res 1 229-235
[2]  
Bugat R(2003)Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002) Br J Cancer 89 S59-S66
[3]  
Fizazi K(2015)Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 26 v133-v138
[4]  
Pavlidis N(2012)Cancer of unknown primary site Lancet 379 1428-1435
[5]  
Pentheroudakis G(2018)Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012 Eur J Cancer 101 77-86
[6]  
Schroten-Loef C(2011)Carcinomas of an unknown primary origin–diagnosis and treatment Nat Rev Clin Oncol 8 701-710
[7]  
Massard C(2009)Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review Cancer Treat Rev 35 221-227
[8]  
Loriot Y(2009)Carcinoma of unknown primary (CUP) Crit Rev Oncol Hematol 69 271-278
[9]  
Fizazi K(2014)Inflammation as a validated prognostic determinant in carcinoma of unknown primary site Br J Cancer 110 208-213
[10]  
Pentheroudakis G(2013)Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature Cancer Treat Rev 39 701-708